TCT 2019: TRILUMINATE Six-Month Results Support Abbott’s TriClip

03 Oct 2019

The six-month results of the TRILUMINATE Feasibility trial support the safety and effectiveness of Abbott’s TriClip, a version of the company’s successful MitraClip adapted to repair the tricuspid valve. The company is now sponsoring a pivotal trial to support FDA approval of TriClip.

Beautiful view of business center in downtown San Francisco in USA at dusk. - Image — • Source: shutterstock.com

The six-month results from the single-arm TRILUMINATE Feasibility trial confirm Abbott Laboratories Inc.’s TriClip, a tricuspid version of Abbott’s MitraClip mitral valve repair device, improves both clinical endpoints and quality of life for patients with tricuspid regurgitation.

Lead investigator Georg Nickenig of University Hospital in Bonn, Germany, presented the data at the Transcatheter Cardiovascular Therapeutics (TCT) conference...